semaglutide
Incretin receptor agonists · 14 suppliers · $0.65 to $25.00 per mg · 755 registered studies · 5,682 indexed papers
This page holds two records that were compiled separately. The research figures below come from the public registries named under each one, each read on the date printed beside it. The supplier prices at the foot were read on the suppliers own sites on the dates in that table. Nothing here was produced by this publication measuring anything.
Identity and computed properties
PubChem holds this compound as CID 56843331, molecular formula C187H291N45O59, average mass 4114 daltons and monoisotopic mass 4111.1154 daltons, read on 2026-09-19. Those masses are computed from the deposited structure and were not measured on any material, so they are the expected value an identity check compares against rather than evidence about any vial.
The title that record carries for the CID is Semaglutide. Its synonym list runs to 38 entries.
Receptors the literature describes
No published paper this search reached describes a receptor this compound acts at.
The registered trial record
An intervention search of clinicaltrials.gov for the term semaglutide, read on 2026-09-19, returned 755 registered studies: 8 early phase 1, 125 phase 1, 148 phase 2, 178 phase 3, 111 phase 4 and 212 recorded with no phase.
Novo Nordisk A/S is lead sponsor on 259 of the 755 records. The remaining 496 name 337 other organizations.
On the date read, the statuses those records carried were 340 completed, 169 recruiting and 98 not yet recruiting, among others.
The earliest record the search returns is NCT00696657, first submitted 2008-06-11. That date is a floor, not an origin: earlier work may sit in the registry under a code number this search term does not match.
Registry counts measure registration, not knowledge.
The publication record
PubMed answered 5,682 records for the term semaglutide on 2026-09-19. Of those, 349 carry a clinical-trial publication type, and 97 of those carry Clinical Trial, Phase III. 1,647 carry the publication type Review, which is other people reading the rest.
PubMed counts measure indexing, so work in venues it does not index is invisible to this figure. The term that produced it is printed above so it can be run again.
Regulatory status
The Drugs@FDA database holds application NDA 213051 under this name, sponsor NOVO. Its listed products are marked Prescription in the same database.
Findings, as published reports recorded them
This block was compiled and no finding from a named publication was reached.
Adverse events, as published reports recorded them
This block was compiled and no adverse event from a named publication was reached.
Spontaneous report databases are not used on this page. A count of reports carries no denominator, so it cannot be read as a rate and is not printed as one.
Who it is not given to
labelThree groups must not be given Ozempic or Rybelsus. Anyone who has had medullary thyroid cancer, anyone whose family has, and anyone with the inherited condition called Multiple Endocrine Neoplasia type 2. Also anyone who has already had a serious allergic reaction to semaglutide.OZEMPIC and RYBELSUS label · read 2026-09-19
labelThe label carries a boxed warning, which is the strongest warning the Food and Drug Administration uses. Semaglutide caused thyroid tumours in rodents, and the dose that did it was in the range people are given. Whether it does the same in people is not known, and the label says so.OZEMPIC and RYBELSUS label · read 2026-09-19
Ozempic and Rybelsus are prescription medicines made by Novo. Powder sold as semaglutide is not either of them, and the thyroid warning above is the reason a doctor asks about family history before prescribing it.read 2026-09-19
Every row is a price read on that supplier's own site, divided by the milligrams it buys. Cheapest first, which is not a ranking of quality: the columns beside the rate show what this publication could confirm about the evidence behind it. Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.
Vendor comparison
| Per mg | Price | Supplier | Certificate checkable | Caution on record | What the figure is |
|---|---|---|---|---|---|
| $0.65per mg | $65.0010mg × 10 vials | reta-peptiderecord → | not transcribed | not transcribed | 10-vial kit, 10mg per vialread 2026-08-20 |
| $0.80per mg | $40.005mg × 10 vials | Qingdao Sigma Chemicalrecord → | not transcribed | not transcribed | 1 kit (10 vials), 5mg per vialread 2026-08-20 |
| $1.31per mg | $131.0010mg × 10 vials | GreyLabsrecord → | not transcribed | not transcribed | 10-vial kit; mg is the per-vial sizeread 2026-08-25 |
| $1.70per mg | $1699.001000mg | BulkGLPrecord → | not transcribed | not transcribed | single listed unit, current price; house code GLP1S expanded as semaglutide in the sentence itselfread 2026-08-26 |
| $3.00per mg | $15.005mg | SCYRXrecord → | not transcribed | not transcribed | single vial current price; sentence states Semaglutide 5mg and Tirzepatide 5mg at $15.00 eachread 2026-08-26 |
| $4.90per mg | $49.0010mg | Vertex Labsrecord → | not checkable | The address and telephone printed on the certificates do not match those the laboratory publishes on its own contact page. City and ZIP agree, street number, suite and telephone do not. No cause has been established. | single vial current priceread 2026-08-24 |
| $4.95per mg | $99.0020mg | BulkGLPrecord → | not transcribed | not transcribed | single listed unit, current price; house code GLP1S expanded as semaglutide in the sentence itselfread 2026-08-26 |
| $8.40per mg | $84.0010mg | VeraChain Labsrecord → | not checkable | Two conflicting molecular weights appear for one compound, and a 5mg certificate is badged on a 10mg product page. | single vial current priceread 2026-08-24 |
| $10.00per mg | $99.9910mg | Apollo Peptide Sciencesrecord → | not transcribed | not transcribed | single vial current price; listed as GLP-1 S, named semaglutide with CAS 910463-68-2 in the listing itselfread 2026-08-25 |
| $12.00per mg | $59.995mg | NuScience Peptidesrecord → | not transcribed | not transcribed | single vial current price; house code GLP-1 SM resolved in the sentence by CAS 910463-68-2read 2026-08-20 |
| $13.00per mg | $65.005mg | Ascension Peptidesrecord → | not transcribed | not transcribed | discounted from 99.99; listed as S-5, identified in the sentence by formula C187H291N45O59 / MW 4114, the page itself neread 2026-08-17 |
| $13.57per mg | $68.005.01mg | Modern Aminosrecord → | not transcribed | not transcribed | single vial current price; house code Modern-S3m expanded to Semaglutide Sodium in the sentenceread 2026-08-17 |
| $13.98per mg | $69.905mg | Evolve Peptidesrecord → | not transcribed | not transcribed | single vial current price (55.92 is the deepest bulk tier, not the single-vial price)read 2026-08-23 |
| $16.00per mg | $79.995mg | Apollo Peptide Sciencesrecord → | not transcribed | not transcribed | single vial current price; listed as GLP-1 S, named semaglutide with CAS 910463-68-2 in the listing itself, which settleread 2026-08-25 |
| $16.50per mg | $165.0010mg | Prime Labsrecord → | not transcribed | not transcribed | single vial current price from catalog dataread 2026-08-26 |
| $25.00per mg | $250.0010mg | Grey Research Peptidesrecord → | not transcribed | not transcribed | single vial current price; listed as GLP-1 10mg, SKU SEMA10MG, with semaglutide named in the sentence from the slug and read 2026-08-25 |
| $25.00per mg | $125.005mg | Prime Labsrecord → | not transcribed | not transcribed | single vial current price from catalog data; homepage tile flagged sold out at the time of the readread 2026-08-26 |
Read between 2026-08-17 and 2026-08-26. Prices move and these were read once.
Sources
Registered study counts, phases, lead sponsors and first-submitted dates: the clinicaltrials.gov public API, one intervention search on the term printed above, read 2026-09-19. Indexed paper counts and publication types: PubMed, the term printed above and that term narrowed by publication type, read 2026-09-19. Formula and computed mass: PubChem, the CID printed above, read 2026-09-19. Application status: the Food and Drug Administration Drugs@FDA database through the agency public endpoint, read 2026-09-19.
The dates in the paragraph above are the dates those fetches ran, stamped in UTC. The dates in the list below are the dates a person read each record. The same record can carry both, a day apart, when a fetch ran after midnight UTC.
- PubChem compound record, CID 56843331 read 2026-09-19
- Food and Drug Administration label record, openFDA drug label endpoint, semaglutide read 2026-09-19